FCRL3 influences the TME indirectly mainly through immunomodulation, which may be associated with the NF-κB inflammatory axis; EFEMP1 promotes tumor metastasis and TME remodeling via EGFR-mediated signaling; ANKRD29 directly regulates the MAPK pathway, exerts a tumor-suppressive effect in NSCLC, and enhances immune responses in the TME. Here, EGFR is linked to neoplasm.